INVEGA SUSTENNA 75 mg Pre-filled syringe

Product Details

INVEGA SUSTENNA 75 mg is formulated as an extended-release injectable suspension in a pre-filled syringe. Each syringe delivers 75 mg of paliperidone palmitate, equivalent to 50 mg of paliperidone. It is designed for intramuscular administration by a healthcare professional, offering a sustained therapeutic effect to help patients adhere to their treatment plan more easily than daily oral medications. The active ingredient is converted into paliperidone in the body, which is the active metabolite of risperidone.

Benefits of Use

• Long-acting formulation for once-monthly administration, improving treatment adherence.
• Effective in managing symptoms of schizophrenia and schizoaffective disorder.
• Helps prevent symptom recurrence and reduce the risk of relapse.
• Administered by a healthcare professional, ensuring correct dosage and technique.
• Offers a consistent therapeutic level of medication, reducing fluctuations experienced with daily oral dosing.

How to Use

INVEGA SUSTENNA must be administered by a healthcare professional.

1. The healthcare provider will prepare the pre-filled syringe for injection, ensuring the suspension is properly mixed.
2. The injection is given into either the deltoid muscle (shoulder) or the gluteal muscle (buttock).
3. The initial dose and subsequent maintenance doses will be determined by your doctor, typically administered once a month.
4. It is crucial to adhere to the prescribed dosing schedule for optimal treatment efficacy.
5. Do not attempt to self-administer this medication.

Ingredients

• Active Ingredient: Paliperidone palmitate 75 mg (equivalent to 50 mg paliperidone)
• Inactive Ingredients: Polysorbate 20, Citric acid monohydrate, Disodium hydrogen phosphate anhydrous, Sodium hydroxide (for pH adjustment), Water for injection.

Caution & Warnings

• This medication should only be administered by a qualified healthcare professional.
• Inform your doctor about all your medical conditions, especially heart problems, kidney or liver disease, diabetes, seizures, or a history of neuroleptic malignant syndrome (NMS) or tardive dyskinesia (TD).
• Avoid alcohol consumption while on this medication.
• May cause drowsiness or affect your ability to drive or operate machinery.
• Monitor for signs of hyperglycemia (high blood sugar) including excessive thirst, frequent urination, increased appetite, and weakness.
• Be aware of potential orthostatic hypotension (dizziness upon standing) and take precautions to prevent falls.
• Report any involuntary movements, especially of the face or tongue, as these could be signs of tardive dyskinesia.
• Not approved for the treatment of dementia-related psychosis in elderly patients due to increased risk of death.
• May cause weight gain, hyperprolactinemia, and changes in cholesterol levels.
• Do not stop treatment abruptly without consulting your doctor.